Report cover image

Monkeypox Treatment Market Size - By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Publisher SPER Market Research Pvt. Ltd.
Published Jan 18, 2023
Length 248 Pages
SKU # SPER18015629

Description

Monkeypox Treatment Market Size- By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032


Global Monkeypox Treatment Market Overview

According to SPER Market Research, the Global Monkeypox Treatment Market is estimated to reach USD 0.23 billion by 2032 with a CAGR of 10.37%. The monkeypox virus is the source of this uncommon but severe illness. Since monkey pox is a contagious disease, it can be spread by sick people, animals, or even contaminated objects. The monkeypox virus results in skin lesions and rashes on every part of the diseased body. Monkeypox symptoms and signs include fever, swollen lymph nodes, aches and chills, and muscle pain.

Impact of COVID-19 on the Global Monkeypox Treatment Market

The recent COVID 19 pandemic has resulted in weakened immunity in those affected, which raises the risk of monkeypox virus infection. Monkeypox market expansion was boosted by a large population that was infected with COVID 19. Businesses across all industries are struggling financially as a result of the global lockdown caused by the corona virus (COVID 19) epidemic.

Scope of the Report:

Report Metric Details
Market size available for years 2019-2032
Base year considered 2021
Forecast period 2022-2032

Segments covered By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User

Regions covered Asia Pacific, Europe, Middle East and Africa, North America, Latin America

Companies Covered Bavarian Nordic, Chimerix, CIDIC Co., Ltd., EMERGENT, Hetero, Olon S.p.A, Piramal Pharma Solutions, SIGA Technologies, Teva Pharmaceutical Industries Ltd.

Global Monkeypox Treatment Market Segmentation:

By Treatment: Based on the Treatment, Global Monkeypox Treatment Market is segmented as; Medications (Analgesics, Antipruritic or Anti-itch drugs, Antipyretics, Antivirals), Vaccine (Smallpox Vaccine, JYNNEOS/Imvanex), Vaccinia Immune Globulin (VIG).

By Region: Over the forecast period, the monkeypox market in Asia Pacific is anticipated to develop at the quickest rate. Other factors contributing to the market expansion in the region include an increase in the number of patients with monkeypox, government activities to raise public awareness, and an increase in demand for the treatment.

Table of Contents

248 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Monkeypox Treatment Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Monkeypox Treatment Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Monkeypox Treatment Market
7. Global Monkeypox Treatment Market, By Treatment, 2019-2032 (USD Million)
7.1 Medications
7.1.1 Analgesics
7.1.2 Antipruritic or Anti-itch drugs
7.1.3 Antipyretics
7.1.4 Antivirals
7.2 Vaccine
7.2.1 Smallpox Vaccine
7.2.2 JYNNEOS/Imvanex
7.3 Vaccinia Immune Globulin (VIG)
8. Global Monkeypox Treatment Market, By Product Type, 2019-2032 (USD Million)
8.1 Creams
8.2 Gels
8.3 Injectable
8.4 Ointment
8.5 Tablets
9. Global Monkeypox Treatment Market, By Dosage Form, 2019-2032 (USD Million)
9.1 Liquid
9.2 Semi Solid
9.3 Solid
10. Global Monkeypox Treatment Market, By Route of Administration, 2019-2032 (USD Million)
10.1 Oral
10.2 Parenteral
10.3 Topical
11. Global Monkeypox Treatment Market, By Age, 2019-2032 (USD Million)
11.1 Adults
11.2 Geriatrics
11.3 Paediatrics
12. Global Monkeypox Treatment Market, By Gender, 2019-2032 (USD Million)
12.1 Female
12.2 Male
12.3 Others
13. Global Monkeypox Treatment Market, By Prescription Type, 2019-2032 (USD Million)
13.1 Over the counter (OTC) drugs
13.2 Prescription (Rx) drugs
14. Global Monkeypox Treatment Market, By End User, 2019-2032 (USD Million)
14.1 Hospital Pharmacy
14.2 Online Pharmacy
14.3 Retail Pharmacy
15. Global Monkeypox Treatment Market, By Region, 2019-2032 (USD Million)
15.1 Global Monkeypox TreatmentSize and Market Share by Region (2019-2025)
15.2 Global Monkeypox TreatmentSize and Market Share by Region (2026-2032)
15.3 Asia-Pacific
15.3.1 Australia
15.3.2 China
15.3.3 India
15.3.4 Japan
15.3.5 South Korea
15.3.6 Rest of Asia-Pacific
15.4 Europe
15.4.1 France
15.4.2 Germany
15.4.3 Italy
15.4.4 Spain
15.4.5 United Kingdom
15.4.6 Rest of Europe
15.5 Middle East & Africa
15.5.1 Kingdom of Saudi Arabia
15.5.2 United Arab Emirates
15.5.3 Rest of Middle East & Africa
15.6 North America
15.6.1 Canada
15.6.2 Mexico
15.6.3 United States
15.7 Latin America
15.7.1 Argentina
15.7.2 Brazil
15.7.3 Rest of Latin America
16. Company Profiles
16.1 Bavarian Nordic
16.1.1 Company details
16.1.2 Financial outlook
16.1.3 Product summary
16.1.4 Recent developments
16.2 Chimerix
16.2.1 Company details
16.2.2 Financial outlook
16.2.3 Product summary
16.2.4 Recent developments
16.3 CIDIC Co., Ltd.
16.3.1 Company details
16.3.2 Financial outlook
16.3.3 Product summary
16.3.4 Recent developments
16.4 EMERGENT
16.4.1 Company details
16.4.2 Financial outlook
16.4.3 Product summary
16.4.4 Recent developments
16.5 Hetero
16.5.1 Company details
16.5.2 Financial outlook
16.5.3 Product summary
16.5.4 Recent developments
16.6 Olon S.p.A
16.6.1 Company details
16.6.2 Financial outlook
16.6.3 Product summary
16.6.4 Recent developments
16.7 Piramal Pharma Solutions
16.7.1 Company details
16.7.2 Financial outlook
16.7.3 Product summary
16.7.4 Recent developments
16.8 SIGA Technologies
16.8.1 Company details
16.8.2 Financial outlook
16.8.3 Product summary
16.8.4 Recent developments
16.9 Teva Pharmaceutical Industries Ltd.
16.9.1 Company details
16.9.2 Financial outlook
16.9.3 Product summary
16.9.4 Recent developments
17. List of Abbreviations
18. Reference Links
19. Conclusion
20. Research Scope

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us